Skip to content

Author

J. D. den Haan

We have 2 of 102 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Siglec-1-targeting single domain antibodies block or enhance pathogen binding to dendritic cells

High-affinity single domain antibodies, (also known as VHHs or Nanobodies) that allo- or orthosterically modulate ligand binding of Siglec-1 are identified and may serve as broad-spectrum pathogen blocking agents.

H. J. Brink, A. Affandi, S. Man et al. · 0 citations
Open access Jul 2026

Siglec-1-targeted nanobodies restrict HIV-1 transmission and infection of dendritic cells

Newly developed single-domain antibodies against Siglec-1 are used against Siglec-1 as a candidate inhibitor to limit HIV-1 transmission and support the development of host-directed nanobody-based strategies to reduce HIV-1 spread.

S. Man, A. Affandi, H. Brink et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.